126 related articles for article (PubMed ID: 38621178)
1. Impact of Various Concentrations of Low-Dose Atropine on Pupillary Diameter and Accommodative Amplitude in Children with Myopia.
Tran HDM; Ha TTX; Tran YH; Coroneo M; Tran TD; Truong TU; Sankaridurg P
J Ocul Pharmacol Ther; 2024 May; 40(4):232-239. PubMed ID: 38621178
[No Abstract] [Full Text] [Related]
2. Effect of low-dose atropine on myopia progression, pupil diameter and accommodative amplitude: low-dose atropine and myopia progression.
Fu A; Stapleton F; Wei L; Wang W; Zhao B; Watt K; Ji N; Lyu Y
Br J Ophthalmol; 2020 Nov; 104(11):1535-1541. PubMed ID: 32086237
[TBL] [Abstract][Full Text] [Related]
3. Maximum atropine dose without clinical signs or symptoms.
Cooper J; Eisenberg N; Schulman E; Wang FM
Optom Vis Sci; 2013 Dec; 90(12):1467-72. PubMed ID: 24076540
[TBL] [Abstract][Full Text] [Related]
4. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2).
Chia A; Chua WH; Cheung YB; Wong WL; Lingham A; Fong A; Tan D
Ophthalmology; 2012 Feb; 119(2):347-54. PubMed ID: 21963266
[TBL] [Abstract][Full Text] [Related]
5. Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control.
Yam JC; Jiang Y; Tang SM; Law AKP; Chan JJ; Wong E; Ko ST; Young AL; Tham CC; Chen LJ; Pang CP
Ophthalmology; 2019 Jan; 126(1):113-124. PubMed ID: 30514630
[TBL] [Abstract][Full Text] [Related]
6. Atropine for the treatment of childhood myopia: effect on myopia progression after cessation of atropine.
Tong L; Huang XL; Koh AL; Zhang X; Tan DT; Chua WH
Ophthalmology; 2009 Mar; 116(3):572-9. PubMed ID: 19167081
[TBL] [Abstract][Full Text] [Related]
7. Two-Year Clinical Trial of the Low-Concentration Atropine for Myopia Progression (LAMP) Study: Phase 2 Report.
Yam JC; Li FF; Zhang X; Tang SM; Yip BHK; Kam KW; Ko ST; Young AL; Tham CC; Chen LJ; Pang CP
Ophthalmology; 2020 Jul; 127(7):910-919. PubMed ID: 32019700
[TBL] [Abstract][Full Text] [Related]
8. Short-term effects of low-concentration atropine eye drops on pupil size and accommodation in young adult subjects.
Kaymak H; Fricke A; Mauritz Y; Löwinger A; Klabe K; Breyer D; Lagenbucher A; Seitz B; Schaeffel F
Graefes Arch Clin Exp Ophthalmol; 2018 Nov; 256(11):2211-2217. PubMed ID: 30145612
[TBL] [Abstract][Full Text] [Related]
9. Differential Effects on Ocular Biometrics by 0.05%, 0.025%, and 0.01% Atropine: Low-Concentration Atropine for Myopia Progression Study.
Li FF; Kam KW; Zhang Y; Tang SM; Young AL; Chen LJ; Tham CC; Pang CP; Yam JC
Ophthalmology; 2020 Dec; 127(12):1603-1611. PubMed ID: 32525048
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for progressive myopia in the atropine therapy for myopia study.
Loh KL; Lu Q; Tan D; Chia A
Am J Ophthalmol; 2015 May; 159(5):945-9. PubMed ID: 25640408
[TBL] [Abstract][Full Text] [Related]
11. The acceptability and visual impact of 0.01% atropine in a Caucasian population.
Loughman J; Flitcroft DI
Br J Ophthalmol; 2016 Nov; 100(11):1525-1529. PubMed ID: 26903521
[TBL] [Abstract][Full Text] [Related]
12. Atropine for the treatment of childhood myopia: changes after stopping atropine 0.01%, 0.1% and 0.5%.
Chia A; Chua WH; Wen L; Fong A; Goon YY; Tan D
Am J Ophthalmol; 2014 Feb; 157(2):451-457.e1. PubMed ID: 24315293
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of 8 Atropine Concentrations for Myopia Control in Children: A Network Meta-Analysis.
Ha A; Kim SJ; Shim SR; Kim YK; Jung JH
Ophthalmology; 2022 Mar; 129(3):322-333. PubMed ID: 34688698
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of Low-Dose Atropine Eyedrops for the Treatment of Myopia Progression in Chinese Children: A Randomized Clinical Trial.
Wei S; Li SM; An W; Du J; Liang X; Sun Y; Zhang D; Tian J; Wang N
JAMA Ophthalmol; 2020 Nov; 138(11):1178-1184. PubMed ID: 33001210
[TBL] [Abstract][Full Text] [Related]
15. Low-Dose 0.01% Atropine Eye Drops vs Placebo for Myopia Control: A Randomized Clinical Trial.
Repka MX; Weise KK; Chandler DL; Wu R; Melia BM; Manny RE; Kehler LAF; Jordan CO; Raghuram A; Summers AI; Lee KA; Petersen DB; Erzurum SA; Pang Y; Lenhart PD; Ticho BH; Beck RW; Kraker RT; Holmes JM; Cotter SA;
JAMA Ophthalmol; 2023 Aug; 141(8):756-765. PubMed ID: 37440213
[TBL] [Abstract][Full Text] [Related]
16. A Meta-Analysis Assessing Change in Pupillary Diameter, Accommodative Amplitude, and Efficacy of Atropine for Myopia Control.
Tran HDM; Sankaridurg P; Naduvilath T; Ha TTX; Tran TD; Jong M; Coroneo M; Tran YH
Asia Pac J Ophthalmol (Phila); 2021 Aug; 10(5):450-460. PubMed ID: 34456234
[TBL] [Abstract][Full Text] [Related]
17. Symptoms and ocular findings associated with administration of 0.01% atropine in young adults.
Cyphers B; Huang J; Walline JJ
Clin Exp Optom; 2023 Apr; 106(3):311-321. PubMed ID: 35188076
[TBL] [Abstract][Full Text] [Related]
18. A multicenter Spanish study of atropine 0.01% in childhood myopia progression.
Pérez-Flores I; Macías-Murelaga B; Barrio-Barrio J;
Sci Rep; 2021 Nov; 11(1):21748. PubMed ID: 34741059
[TBL] [Abstract][Full Text] [Related]
19. Higher order aberrations and axial elongation in combined 0.01% atropine with orthokeratology for myopia control.
Vincent SJ; Tan Q; Ng ALK; Cheng GPM; Woo VCP; Cho P
Ophthalmic Physiol Opt; 2020 Nov; 40(6):728-737. PubMed ID: 32888318
[TBL] [Abstract][Full Text] [Related]
20. Bifocal & Atropine in Myopia Study: Baseline Data and Methods.
Huang J; Mutti DO; Jones-Jordan LA; Walline JJ
Optom Vis Sci; 2019 May; 96(5):335-344. PubMed ID: 31046016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
